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In the article by Levine GM, Bates ER, Blankenship JC, et al., “2011 ACCF/AHA/SCAI Guideline for Percutaneous
Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” which
originally published online November 7, 2011, and appeared in the December 6, 2011, issue of the Journal (J Am Coll
Cardiol 2011;58:2550-83; doi:10.1016/j.jacc.2011.08.008), the following corrections are necessary:
1. In Section 4.9. Periprocedural Myocardial Infarction Assessment (p. 2564), in the Class I recommendation, “creatinine
kinase-MB and troponin I or T should be measured” should be changed to “creatine kinase-MB and/or troponin I or T
should be measured” so that the recommendation reads, “In patients who have signs or symptoms suggestive of MI during
or after PCI or in asymptomatic patients with significant persistent angiographic complications (e.g., large side-branch
occlusion, flow-limiting dissection, no-reflow phenomenon, or coronary thrombosis), creatine kinase-MB and/or
troponin I or T should be measured. (Level of Evidence: C).”
2. In Section 4.9. Periprocedural Myocardial Infarction Assessment (p. 2564), in the Class IIb recommendation, “creatinine
kinase-MB and/or troponin I or T” should be changed to “creatine kinase-MB and/or troponin I or T” so that the
recommendation reads, “Routine measurement of cardiac biomarkers (creatine kinase-MB and/or troponin I or T) in all
patients after PCI may be reasonable. (Level of Evidence: C).”
doi:10.1016/j.jacc.2012.01.010
In the article by Levine GM, Bates ER, Blankenship JC, et al., “2011 ACCF/AHA/SCAI Guideline for Percutaneous
Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” which originally published
online November 7, 2011, and appeared in the December 6, 2011, issue of the Journal (J Am Coll Cardiol 2011;58:e44–122;
oi:10.1016/j.jacc.2011.08.007), the following corrections were necessary:
. In Table 12 (p. e78), the dosing for argatroban in the third column, “Patient Has Not Received Prior Anticoagulant
Therapy” has been changed from “350 mcg/kg bolus, then 15 mcg/kg per min IV infusion” to “350 mcg/kg bolus, then
25 mcg/kg per min IV infusion.”
. In Section 5.10. Periprocedural MI Assessment: Recommendations (p. e83), in the Class I recommendation, “creatinine
kinase-MB and troponin I or T should be measured” has changed to “creatine kinase-MB and/or troponin I or T should
be measured” so that the recommendation now reads, “In patients who have signs or symptoms suggestive of MI during
or after PCI or in asymptomatic patients with significant persistent angiographic complications (e.g., large side-branch
occlusion, flow-limiting dissection, no-reflow phenomenon, or coronary thrombosis), creatine kinase-MB and/or
troponin I or T should be measured. (Level of Evidence: C).”
. In Section 5.10. Periprocedural MI Assessment: Recommendations (p. e83), in the Class IIb recommendation,
“creatinine kinase-MB and/or troponin I or T” has changed to “creatine kinase-MB and/or troponin I or T” so that the
recommendation now reads, “Routine measurement of cardiac biomarkers (creatine kinase-MB and/or troponin I or T)
in all patients after PCI may be reasonable. (Level of Evidence: C).”
doi:10.1016/j.jacc.2012.01.011
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In the paper above, the author EA Meinders name was listed incorrectly. It should be listed as A. Edo Meinders. To make
it clear, it should be Meinders AE.
The authors apologize for this error.
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